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Abstract
Purpose: The aim of this study was to determine changes in human papillomavirus (HPV) 
prevalence among young men from a Midwest metropolitan area over the six years after vaccine 
introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine 
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impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine 
associations between number of vaccine doses and HPV prevalence.
Methods: Men aged 14–26 years reporting male-female and/or male-male sexual contact were 
recruited from a primary care clinic, sexually transmitted disease clinic, and community setting 
during two waves of data collection: 2013–2014 (N = 400) and 2016–2017 (N = 347). Participants 
completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence 
of any (≥1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using 
propensity score weighted logistic regression. Associations between number of doses and HPV 
infection were determined using chi-square tests and logistic regression.
Results: The proportion of men with a history of ≥1 HPV vaccine doses increased from 23% to 
44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with ≥1 vaccine-
type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 
0.62, 95% confidence interval [CI] = 0.44–0.88) and unvaccinated men (32% to 21%; 36% 
decrease; OR = 0.56, 95%CI = 0.34–0.86); there was a non-significant decrease (21%) among 
vaccinated men. Associations between number of doses and HPV prevalence were not statistically 
significant.
Conclusions: Prevalence of vaccine-type HPV decreased among all, vaccinated, and 
unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and 
herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in 
unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued 
monitoring and efforts to vaccinate men prior to sexual initiation are warranted.
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1. Introduction
Human papillomavirus (HPV) vaccination for men was recommended by the U.S. Centers 
for Disease Control and Prevention in 2011. Clinical trials have demonstrated that HPV 
vaccines have high efficacy in men [1]. However, the impact of the HPV vaccine among men 
after the introduction of HPV vaccines into the community is not well characterized. 
Evidence from the first nationally representative study of HPV prevalence in men in the 
United States in 2013–2014 show lower rates of vaccine-type HPV among younger men, 
compared to older men, suggesting that vaccination has reduced HPV prevalence [2]. The 
impact may be due to direct protection of vaccinated men or herd protection of unvaccinated 
men due to HPV vaccination efforts that began for women in 2006. Herd protection after 
HPV vaccine introduction for women has been described in unvaccinated women [3-6] and 
early evidence suggests herd protection among unvaccinated men [7,8].
During the study period, routine vaccination was recommended for men 11–12 years of age, 
catch-up vaccination was recommended for unvaccinated men 13–21 years of age, and 
permissive use was recommended for men aged 22–26 who had sex with men or were 
immunocompromised. Routine HPV vaccination was recommended for women 11–12 years 
of age, and catch-up vaccination was recommended for women 13–26 years of age. In 2016, 
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the HPV vaccine dosing schedule was changed from three doses for 9 to 26 year olds to two 
doses for those initiating vaccination between ages 9 to 14 years and three doses for those 
initiating vaccination at 15 years of age or older. This change was supported by 
immunogenicity data demonstrating that 9–14 year-olds had higher antibody titers after 
vaccination than 16–26 year-olds, the age group included in the majority of clinical efficacy 
trials [9]. Little evidence for real-world vaccine effectiveness of the 2-dose schedule is 
available.
To better understand HPV vaccine impact and herd protection in a community setting, we 
conducted two surveillance studies in a Midwest metropolitan area of the United States in 
2013–2014 and 2016–2017 involving recruitment of unique cohorts of sexually active, 
vaccinated and unvaccinated, young men (aged 13–26 years) at two time points after HPV 
vaccine introduction from the same urban community to assess HPV prevalence. The 
primary aim of this study was to examine changes in the prevalence of 4-valent vaccine-type 
HPV (HPV6, 11, 16 and/or 18) infection in young men recruited from clinical and 
community settings from 2013–14 (wave 1) to 2016–17 (wave 2). We examined changes in 
HPV prevalence overall and stratified by vaccination status (vaccinated and unvaccinated). 
We examined changes in HPV prevalence in vaccinated men to determine vaccine impact 
and in unvaccinated men to determine herd protection. Additionally, we conducted stratified 
analyses to examine vaccine impact by men who initiated sex after vaccination, men who 
initiated sex before vaccination, recruitment site, and age at study enrollment. An 
exploratory aim was to examine, among men from waves 1 and 2 combined, the association 
between number of doses and HPV prevalence among all men, among men who received 
their first HPV vaccine dose at 15 years of age or older, and among men who initiated sex 
after vaccination and men who initiated sex before vaccination.
2. Methods
Participants were 13–26 year old men with a history of sexual contact (genital-oral, genital-
genital) with one or more male or female partners, recruited in 2013–2014 (wave 1) and 
2016–2017 (wave 2). We recruited men using a sequential sampling strategy. Men were 
recruited from a hospital-based adolescent primary care clinic (Teen Health Center, THC), 
health department sexually transmitted disease (STD) clinics and the community. 
Recruitment from the community included advertising in print and digital media (both in the 
community – e.g. university and larger community), mailing lists maintained by the Division 
of Infectious Diseases and the Office of Clinical and Translational Research, and 
advertisements to hospital employees. Participants provided written informed consent. 
Parental consent for minors was waived because an inclusion criterion was sexual contact, 
and disclosure of this criterion could breach patient confidentiality. During recruitment for 
wave 2, potentially eligible participants were excluded if they had participated in wave 1. 
The study was reviewed and approved by the institutional review boards of the hospital and 
the health department where recruitment occurred.
Participants completed a validated paper/pencil survey, available in English and Spanish 
[10]. The survey assessed participant’s sociodemographic characteristics, HPV vaccination 
history, substance use history, and sexual behaviors. HPV vaccination history, including date 
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of vaccinations and vaccine type received, was verified by electronic medical record (EMR) 
and/or the Ohio Impact Statewide Immunization System. Documentation in at least one of 
these systems was available for 85% of the participants who reported having received the 
vaccine. All vaccinations have been entered into the EMR system in these settings since the 
HPV vaccine was approved for men [11].
Sample collection and testing has been described previously [12]. In short, a trained study 
team member used separate, moistened swabs to collect samples of the glans penis, 
including coronal sulcus; penile shaft; scrotum; and the perianal/anal area. Prior to DNA 
extraction, samples from the genital areas (glans, shaft, and scrotum) were combined; genital 
and perianal/anal samples were analyzed separately [13]. Roche Linear Array (Roche 
Molecular Systems, Alameda, CA) was used to detect individual high-risk and low-risk 
genotypes.
2.1. Outcome and independent variables
The primary outcome variable was at least one 4-valent vaccine-type HPV (HPV6, 11, 16 
and/or 18). Secondary outcomes were high-risk vaccine-type HPV (HPV16 and/or 18), low-
risk 4-valent vaccine-type HPV (HPV6 and/or 11), and ≥1 HPV type. An individual was 
considered infected with an HPV type if that type was detected from the genital and/or 
perianal/anal sample.
Independent variables included sociodemographic characteristics; HPV vaccination history; 
reproductive health history, including history of sexually transmitted infections, age of first 
sex, and number of lifetime sexual partners; and sexual behaviors, including condom use, 
number and gender of recent sexual partners and sexual practices. Men with verified and 
self-report of vaccination were included in analyses. Age of first HPV vaccine dose was 
calculated from date of vaccination and date of birth. A variable was calculated to describe 
the timing of initiation of vaginal intercourse (subsequently referred to as sexual initiation) 
related to vaccination among men who reported sexual intercourse with women. This 
variable was calculated using self-reported age of first vaginal intercourse and age of first 
HPV vaccine dose.
2.2. Statistical analyses
Descriptive statistics were used to summarize independent variables overall and stratified by 
vaccination status (vaccinated and unvaccinated) in wave 1 and wave 2. We first compared 
participants in wave 1 and wave 2 to determine if there were differences in demographic 
characteristics, health history and behaviors, and sexual history and behaviors that have been 
associated with HPV infection in previous studies (Table 1). Comparisons were tested for 
significance (p < 0.05) using Chi square, Fisher’s exact test, two-sample t-test or Wilcoxon 
rank-sum test, as appropriate. Between-waves comparisons were completed for all men, 
vaccinated men, unvaccinated men, and stratified analyses of vaccinated and unvaccinated 
men. Additional stratified analyses were conducted among vaccinated men by sexual 
initiation after vaccination, sexual initiation before vaccination, recruitment site (THC and 
STD clinic only, as the number of participants from the community in wave 1 was low), and 
age (14–18 years and 1926 years). Additional stratified analyses were conducted among 
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unvaccinated men by recruitment site (THC, STD clinic, and community) and age (14–21 
years and 22–26 years). Age categories were different for vaccinated and unvaccinated men 
in the stratified analyses due to differences in distribution of age in vaccinated and 
unvaccinated men.
As there were a number of statistically significant differences in comparison of participants 
in waves 1 and 2, propensity score analyses based on inverse probability of treatment 
weighting was performed for each between-wave comparison [5,14]. Each propensity score 
analysis used candidate variables listed in Table 1, with the exception that stratified analyses 
did not include stratified variables. Logistic regression models were used in propensity score 
analyses. The propensity score is the probability that a participant belongs to a naturally 
occurring treatment group based on a set of background characteristics. The propensity score 
adjusts for selection bias in an observational study, allowing one to analyze an observational 
study so that it mimics the characteristics of a randomized controlled trial. It provides a one-
dimensional summary of multidimensional covariates, X, such that when the propensity 
scores are balanced across the two treatment groups, the distribution of observed baseline 
covariates is similar between participants in the two groups [5]. After the propensity score 
analyses, all previously unbalanced variables were balanced.
Proportions of HPV-infected men were calculated for each outcome variable, overall and 
stratified by vaccination status (vaccinated and unvaccinated), in each of the two waves both 
before and after propensity score adjustment. Logistic regression analysis with HPV 
infection as the outcome and wave as the independent variable were used to estimate odds of 
HPV prevalence across the study waves, unadjusted and adjusted for the propensity score 
[5,15-18]. Because all variables were balanced after propensity score analysis, no baseline 
variables were included as covariates in logistic regression models adjusted for the 
propensity score.
Analyses of vaccine-type HPV infection among vaccinated men were then stratified by 
sexual initiation after vaccination, sexual initiation before vaccination, recruitment site (THC 
and STD clinic only, as the number of participants from the community in wave 1 was low), 
and age (14–18 years and 19–26 years). Analyses of unvaccinated men were stratified by 
recruitment site (THC, STD clinic, and community) and age (14–21 years and 22–26 years; 
categories were different for vaccinated and unvaccinated men due to distribution of age). 
Logistic regression analysis with vaccine-type HPV infection as the outcome and wave as 
the independent variable were used to estimate odds of vaccine-type HPV prevalence across 
the study waves, unadjusted and adjusted for the propensity score. Because all baseline 
variables were balanced after propensity score analysis, no baseline variables were included 
as covariates in logistic regression models adjusted for the propensity score.
To examine associations between number of vaccine doses and HPV prevalence, we 
categorized number of doses received before study enrollment (0, 1, 2, and ≥3). We 
examined the associations between number of doses and HPV infection (4-valent vaccine-
type HPV and ≥1 HPV type) using a Chi-square test and Cochran-Armitage Trend test. We 
then conducted logistic regression analyses with infection (4-valent vaccine-type and ≥1 
HPV type) as the outcome variable and number of doses as the predictor variable. We then 
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repeated these analyses among the subset of men who received their first dose at 15 years of 
age or older, men who initiated sex after vaccination, and men who initiated sex before 
vaccination. Data analyses were conducted using SAS version 9.4 (SAS Institute, Cary NC).
Two post hoc analyses were conducted. The first, using prevalence of HPV in the study 
population, examined the power to detect a significant (p < 0.05) difference in vaccine-type 
HPV prevalence among vaccinated men between waves. With a sample size of 242 
vaccinated men and 471 unvaccinated men and a vaccine-type HPV prevalence of 25.5% in 
unvaccinated men, this study had 80% power to detect a decrease of 36% (from 25.5% to 
16.4%) for vaccinated men. The second, compared vaccine-type HPV prevalence among 
vaccinated men who initiated sex with women after and before vaccination (waves 1 and 2 
combined). Men who reported sexual initiation at the same age as HPV vaccination were 
excluded from this analysis.
3. Results
A total of 875 men were approached and 747 (85.4%) enrolled: 400 in wave 1 and 347 in 
wave 2. Comparison of those screened but not enrolled and those enrolled demonstrated that 
enrollment was higher among men who reported Black vs. White or other race, men with 
private vs. public or no insurance, and men who were older vs. younger.
The proportion of vaccinated men increased from 22.5% (n = 90) in wave 1 to 43.5% (n = 
163) in wave 2 (p < 0.001). The mean age of vaccination decreased from 16.2 years (SD 2.3) 
in wave 1 to 15.1 years (SD 2.3) in wave 2 (p < 0.01). All men in wave 1 received only 4-
valent HPV vaccine (Merck & Co., Inc.). Of the 160 men in wave 2 for whom the specific 
HPV vaccine (4-valent or 9-valent) they received was recorded in their medical record, 125 
(78.1%) received only 4-valent HPV vaccine, 12 (7.5%) received only 9-valent HPV vaccine 
(Merck & Co., Inc.); the remaining 23 (14.4%) received a combination of 4-valent and 9-
valent HPV vaccine doses.
Characteristics of participants are shown in Table 1. A majority (>65%) self-identified as 
Black. The average age of men was 21.5 (standard deviation [SD] 3.1) years and 21.0 (SD 
3.0) years in waves 1 and 2, respectively (p = 0.04). The highest proportion of men were 
recruited from the STD clinic, followed by the THC and community. About one-third of 
participants initiated vaginal intercourse at 14 years or younger: 34.5% in wave 1 and 30.5% 
in wave 2. The proportion of vaccinated participants who reported vaginal intercourse before 
vaccination was 47.8% in wave 1 and 39.3% in wave 2 (p = 0.02).
3.1. Proportions of men with HPV in wave 1 and wave 2
Table 2 shows the proportions with ≥1 HPV type, 4-valent vaccine-type HPV, HPV16 and/or 
18, and HPV6 and/or 11 by wave among all men, vaccinated men, and unvaccinated men. 
The proportion of men infected with ≥1 HPV type increased, although not significantly, 
from wave 1 to wave 2 among all men (62.8–69.0%, adjusted; 10% increase), vaccinated 
(57.0–63.5%, adjusted; 11% increase), and unvaccinated men (67.1–69.8%, adjusted; 4% 
increase).
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The proportion of men infected with 4-valent vaccine-type HPV decreased significantly 
from wave 1 to wave 2 among all men (28.8–20.0%, adjusted; 31% decrease, odds ratio 
[OR] 0.62, 95% confidence interval [Cl] 0.44–0.88]) and unvaccinated men (32.2–20.5%, 
adjusted; 36% decrease, OR 0.56 [95% CI 0.34–0.86]). The decrease in vaccinated men 
(25.7–20.0%, adjusted; 21% decrease) was not statistically significant.
Similarly, the proportion of men infected with HPV16 and/or 18 decreased significantly 
from wave 1 to wave 2 among all men (26.1–16.5%, adjusted; 37% decrease, OR 0.56 
[95%CI 0.39–0.81]) and unvaccinated men (29.2–15.7%, adjusted; 44% decrease, OR 0.47 
[95%CI 0.29–0.77]). The decrease in vaccinated men (24.4–19.9%, adjusted; 19% decrease) 
was not statistically significant.
The proportion of men infected with HPV6 and/or 11 did not change significantly for all, 
vaccinated, or unvaccinated men. The adjusted proportion of vaccinated men infected with 
HPV6 and/or 11 decreased 40% from 1.5% to 0.9%, but the decrease was not significant.
Fig. 1 demonstrates that among vaccinated men, there were no statistically significant 
differences in vaccine-type HPV infection between waves 1 and 2 by sexual initiation after 
or before vaccination, recruitment site, or age. Among unvaccinated men enrolled in the 
community, the proportion of those with vaccine-type HPV decreased significantly from 
wave 1 to wave 2 (31.4% vs. 9.7%, p = 0.02). Among 14–21 year old unvaccinated men, the 
proportion of those with 4-valent vaccine-type HPV decreased from wave 1 to wave 2 
(35.0% vs. 13.0%, p<0.01, 62.9% decrease). Among 22–26 year old unvaccinated men, the 
proportion of those with 4-valent vaccine-type HPV decreased, but not significantly, from 
wave 1 to wave 2 (35.0% vs. 13.0%, p > 0.05, 29.8% decrease). In post hoc analyses, a 
significantly higher proportion of men who reported sexual initiation before vaccination (33 
of 128 men [25.8%]) had 4-valent vaccine-type HPV infection compared to men who 
reported sexual initiation after HPV vaccination (14 of 95 men, [14.7%]) (p = 0.05 Chi 
square test).
3.2. HPV prevalence and number of vaccine doses
Among the 746 men from waves 1 and 2, 471 were unvaccinated (63.1%), 58 (7.8%) had 
received 1 dose, 37 (5.0%) received 2 doses, and 143 (19.1%) received 3 or more doses; 38 
(5.1%) had missing data on number of doses. There were no statistically significant 
differences in the proportions of men infected with ≥1 4-valent vaccine-type HPV who 
received no HPV vaccine doses (25%, n = 120 positive), 1 dose (19%, n = 11 positive), 2 
doses (27%, n = 10 positive), and 3 or more doses (22%, n = 31 positive). The number of 
doses was not associated with ≥1 HPV type or HPV16 and/or 18. There were no statistically 
significant differences in proportion of men infected with ≥1 4-valent vaccine-type HPV by 
number of doses among men who were vaccinated at ≥15 years of age, had sexual initiation 
after vaccination, and had sexual initiation before vaccination. The number of doses was not 
associated with >1 HPV type among men vaccinated at >15 years (data not shown).
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In this study of young men recruited from clinical and community settings after HPV 
vaccine introduction, we demonstrated that between 2013–2014 and 2016–2017, the 
proportion of men infected with 4-valent vaccine-type HPV and with HPV16 and/or 18 
decreased from wave 1 to wave 2 among all men, vaccinated men, and unvaccinated men: 
decreases were statistically significant only among all and unvaccinated men. Among the 
relatively small number of vaccinated men, we found no associations between number of 
doses and HPV prevalence.
The decrease in any type HPV prevalence in men from wave 1 to wave 2 may be due to herd 
immunity induced by vaccination of women since 2006. The decrease in 4-valent vaccine-
type HPV and HPV16/18 in all men appears to be primarily due to decreases in 
unvaccinated men. It is likely that unvaccinated men are incurring protection from herd 
immunity. Prevalence decreased in vaccinated men, although the change was not statistically 
significant. The lower magnitude of decline in vaccinated men than in unvaccinated men 
may be due to demographic or behavioral differences between vaccinated and unvaccinated 
men. Unmeasured characteristics of participants may also account for this difference, but 
this conclusion is unlikely. Additionally, it is unlikely that, over time, herd protection will 
offer greater protection than direct protection from the vaccine. These findings are not 
unexpected and are supported by modeling data examining the impact on HPV prevalence 
among men; if a male vaccination program is added to an existing female vaccination 
program, decreases in HPV prevalence are gradual and continue for many years after the 
implementation of the male vaccination program [19]. Continued surveillance is necessary 
to fully describe the impact of the HPV vaccination program in men.
The significant decrease in 4-valent vaccine-type HPV infection in unvaccinated men 
suggests that men are benefitting from vaccination efforts in women that have led to lower 
HPV prevalence among women, i.e., men are benefitting from herd protection from vaccine-
type HPV infection. In studies of women recruited from the same geographic area from 
2006 to 2017, high vaccine effectiveness among women was suggested by a decrease of 
80.9% in the prevalence of 4-valent vaccine-type HPV among vaccinated women [17]. 
Additionally, a decrease of 40% in the prevalence of 4-valent vaccine-type HPV was noted 
among unvaccinated women [18]. Thus men recruited into this study between 2013 and 
2017 may have benefited from decreasing HPV prevalence among women with whom they 
have sexual contact. Herd protection of men from vaccination of women is further supported 
by our findings of significant decreased 4-valent vaccine-type HPV among 14–21 year-olds 
but not 22–26 year-olds. Younger men in wave 2 appear to have benefited from HPV 
vaccination efforts among women.
Our data are consistent with a retrospective observational study based in Australia which 
tested for HPV in archived urine and urethral swabs from a Chlamydia trachomatis 
screening program that demonstrated a decrease in 4-valent vaccine-type HPV among men 
during the period of widespread vaccination of women [8]. As increases in HPV vaccination 
rates in women occurred in 2013–14 and 2016–17, prevalence of HPV in males decreased. 
The occurrence of herd protection was supported by greater decreases of HPV infection in 
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Australian men versus immigrants from countries with low vaccination rates. Our findings 
are also consistent with findings from an Australian-based HPV prevalence study of 
unvaccinated men during a time when younger women had a high vaccination coverage 
compared to older women. The authors found that younger men, who were likely to have 
had sexual contact with similarly aged women, had lower rates of HPV than older men, who 
were likely to have had more sexual contact with older, unvaccinated women [7].
The decreases in 4-valent vaccine HPV types and HPV16/18 among vaccinated men 
between waves 1 and 2 were not statistically significant. This may be due to the fact that a 
high proportion of men in both waves were vaccinated after sexual initiation. However, a 
21% decrease in the proportions of vaccinated men with vaccine-type HPV infection 
between wave 1 and wave 2 is clinically significant, although ad hoc power analysis 
indicated that the study sample size did not have adequate power to detect the effect size we 
observed in this study. The decreases in proportion of vaccinated men with HPV 16/18 and 
HPV 6/11 is also reassuring when considering the impact of vaccination. Although the 
proportion of vaccinated men with HPV6/11 decreased by 40%, the change was not 
significant, likely because there were so few men who were infected with HPV 6 or 11, 
thereby limiting power to detect a significant decrease in prevalence. Therefore, continued 
surveillance will be needed to show changes in vaccine-type HPV and HPV 6/11 after 
vaccine introduction. We expect the prevalence in vaccine-type HPV among vaccinated men 
will continue to decrease with continued vaccination efforts; however, continued 
surveillance will be necessary to confirm this.
When analyses were stratified by age, sexual initiation after vaccination, sexual initiation 
before vaccination, and recruitment site, there were no statistically significant changes in 
HPV prevalence among vaccinated men from wave 1 to wave 2. Increases in vaccine-type 
prevalence in the stratified analysis of vaccinated men are most likely due to uncertainty of 
the measurement due to the low number of vaccinated men infected with HPV. Differences 
in unmeasured participant characteristics may explain the nonsignificant changes between 
waves 1 and 2, although this is unlikely. The sample sizes of vaccinated men in the different 
categories may have been too small to detect significant differences. When analysis included 
vaccinated men from both waves, prevalence was significantly lower among men who 
initiated sex after vaccination compared to before vaccination. This is expected and supports 
the 11–12 year old target age for vaccination in men.
The prevalence of any HPV increased, although not statistically significantly, from wave 1 to 
2 among all, vaccinated and unvaccinated men. Continued surveillance of HPV prevalence 
among men is important to determine if this trend towards increasing overall HPV 
prevalence persists. Our previous work in women suggests that some observed changes in 
non-vaccine HPV types in men may be explained by different sociodemographic and 
behavioral characteristics in vaccinated vs. unvaccinated men that correlate with HPV 
prevalence [16]. Analysis of changes in non-vaccine HPV types in men is important to 
assess if cross-protection and type-replacement are occurring, however these analyses are 
beyond the scope of this paper examining vaccine impact and herd protection. Among 
women, evidence from clinical trials and real-world based studies have demonstrated cross-
protection [15,20-22]. Evidence of type-replacement is less conclusive, some studies suggest 
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type-replacement may be occurring [22-24] while others demonstrate no type replacement 
[25-27].
Prompted by changes in vaccination recommendations for men 14 years and younger to 
receive two HPV vaccine doses, rather than the previously recommended three doses [9], we 
examined the association of 4-valent vaccine-type HPV infection with number of doses 
among men from both waves 1 and 2. In this study, 4-valent vaccine-type HPV infection was 
not associated with number of doses. Although we anticipated a higher proportion of 
unvaccinated men to be infected compared to men who had received 1, 2, or 3 vaccine doses, 
both participant characteristics and the low number of vaccinated men with HPV infection 
may explain our findings. Because of the high prevalence of HPV in this community, it is 
likely we detected HPV in vaccinated men that was acquired before vaccination. The lack of 
association between prevalence of HPV and number of vaccine doses among men who 
initiated vaginal intercourse after vaccination is likely due to men acquiring HPV prior to 
vaccination from sexual behaviors other than vaginal intercourse. Previous studies in women 
[28-30] and men [31] have shown that HPV may be acquired prior to initiation of vaginal 
intercourse, and we did not control for other types of sexual contact. It is also possible that 
differences in demographic and sexual behaviors between vaccinated and unvaccinated men 
that were not included in the analysis may be associated with HPV prevalence. However, 
differences in the number of infected men in each dose category may have been too small to 
detect with the current sample size. It will be important to examine the association of HPV 
infection with number of vaccine doses in men ≥15 years old to provide information 
necessary to evaluate the need for two vs. three vaccine doses.
There are a number of reasons that men who were vaccinated prior to sexual initiation might 
have had vaccine-type HPV detected: this finding does not indicate vaccine failure. First, 
participants were not asked directly about the timing of vaccination in relation to sexual 
initiation; therefore some participants may have been miscategorized as having had been 
vaccinated after sexual initiation. In addition, the participants may have acquired HPV 
through behaviors other than vaginal intercourse: the calculated variable did not include age 
of first oral sex or anal sex. The finding of a lower prevalence of vaccine-type HPV among 
men who were vaccinated prior to (vs. after) initiating vaginal intercourse is expected, and 
supports the 11–12 year old target age for vaccination in men so that they are vaccinated 
prior to sexual initiation.
In conclusion, findings from this study suggest herd protection is occurring among 
unvaccinated men in the first six years after HPV vaccination was initiated in men, and 11 
years after HPV vaccination was initiated among women in the United States. Continued 
surveillance of HPV infection among men will be critical to fully assess vaccine impact as 
vaccination efforts continue. Despite evidence of herd protection, men remain at high risk 
for HPV infection. Continued vaccination efforts among men and women are critical for 
men to realize the benefits offered by HPV vaccination. Clinical and public health efforts to 
vaccinate men prior to sexual initiation are important for realization of the full benefits 
offered by HPV vaccination.
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(top) Proportion (adjusted) and standard error of the mean of vaccinated men infected with 
≥1 4-valent vaccine-type HPV stratified by sexual initiation after vaccination, sexual 
initiation before vaccination, recruitment from the Teen Health Center (THC), recruitment 
from the STD clinic, 14–18 years of age at time of enrollment, and 19–26 years of age at 
time of enrollment. Too few participants recruited from the community were vaccinated in 
wave 1 to conduct stratified analyses. Differences between wave 1 and 2 were tested for 
significance using logistic regression. Results represented in this Figure cannot be used to 
infer differences in characteristics or HPV prevalence between vaccinated and unvaccinated 
men. (bottom) Proportion (adjusted) and standard error of the mean of unvaccinated men 
infected with ≥1 4-valent vaccine-type HPV stratified by recruitment from the Teen Health 
Center (THC), recruitment from the STD clinic, recruitment from the community, 14–21 
years of age at time of enrollment, and 22–26 years of age at time of enrollment. Differences 
between wave 1 and 2 were tested for significance using logistic regression. Results 
represented in this Figure cannot be used to infer differences in characteristics or HPV 
prevalence between vaccinated and unvaccinated men.
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